Spruce Biosciences, Inc.
SPRB and SPRBDSpruce Biosciences is a biopharmaceutical company dedicated to developing and commercializing novel therapies for neurological and endocrine disorders with significant unmet medical needs.
Earnings
Next report
Nov 9, 2026 (in 2 months)Competitors
By market cap
By revenue growth
Profile
Spruce Biosciences is a biopharmaceutical company dedicated to developing and commercializing novel therapies for neurological and endocrine disorders with significant unmet medical needs. The company focuses on diseases with well-understood biology where current treatment options are either nonexistent or suboptimal. Its primary strategy involves advancing a pipeline of small molecule and biologic candidates through clinical development toward global commercialization.
A clinical-stage developer targeting ultra-rare conditions like MPS IIIB and CAH with orphan-designated candidates.
FAQ
- What is Spruce Biosciences, Inc.'s market cap?
- Spruce Biosciences, Inc. (SPRB) has a market capitalization of $176.7M and trades on NASDAQ.
- Who are Spruce Biosciences, Inc.'s competitors?
- Spruce Biosciences, Inc.'s key competitors include Neurocrine Biosciences, Inc., Fulcrum Therapeutics, Inc. Common Stock, Septerna, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Spruce Biosciences, Inc. partner with?
- Spruce Biosciences, Inc.'s notable partners include Eli Lilly and Company, BioMarin Pharmaceutical Inc., HMNC Holding GmbH, and others.
- Where is Spruce Biosciences, Inc. headquartered?
- Spruce Biosciences, Inc. is headquartered in United States of America and employs approximately 22 people. It has been publicly traded since 2020.